|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2020-06-11 |
|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2020-01-21 |
|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期1990-12-20 |
An Open-label Single-arm Clinical Study to Assess the Efficacy and Safety of Inebilizumab in Chinese Adult Patients With Neuromyelitis Optica Spectrum Disorders (NMOSD)
To assess the efficacy and safety of Inebilizumab in Chinese adult patients with neuromyelitis optica spectrum disorders.
在视神经髓系谱系疾病(NMOSD)成人患者中评估伊奈利珠单抗(Inebilizumab)的疗效和安全性的开放单臂临床研究
在中国NMOSD成人患者中评估伊奈利珠单抗的疗效和安全性
An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability ofDaxdilimab (HZN-7734) in Subjects with Systemic Lupus Erythematosus - RECAST SLE OLE
100 项与 Horizon Therapeutics Ireland DAC 相关的临床结果
0 项与 Horizon Therapeutics Ireland DAC 相关的专利(医药)
100 项与 Horizon Therapeutics Ireland DAC 相关的药物交易
100 项与 Horizon Therapeutics Ireland DAC 相关的转化医学